Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO, an Interchangeable Biosimilar to Lucentis

Zydus Lifesciences Ltd has entered into a strategic partnership with Bioeq AG for the licensing, supply and commercialization of Bioeq’s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO, an interchangeable biosimilar of Lucentis for the U.S. market. The Biologics License Application (BLA) for NUFYMCO has been approved by U.S. Food and Drug Administration (USFDA). This partnership will leverage Zydus’ extensive distribution network and strong sales and marketing capabilities across the US to broaden treatment options for patients.